Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop what it calls "synthetic biotic" therapies for Crohn's disease and ulcerative colitis.
Synlogic Links Up With AbbVie For IBD Microbiome Therapies
Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop what it calls "synthetic biotic" therapies for Crohn's disease and ulcerative colitis.